Axon Enterprise (NASDAQ:AXON) Reaches New 1-Year Low - What's Next?

Key Points

• 52-week low: Shares of Axon fell to a new 52-week low of $387.80 (last $391.40), down about 6.8% on the day and trading well below its 50‑day ($478.24) and 200‑day ($575.44) moving averages.
• Analysts remain mostly positive with 16 Buys and 3 Holds and an average price target of $762.93, though several firms recently trimmed targets (e.g., RBC to $735, UBS to $570), showing divergence on near‑term outlooks.
• Beat on results: Axon reported Q4 EPS $2.15 vs. $1.60 est. and revenue $796.7M (+38.5% YoY); meanwhile insiders have sold shares recently even as institutional investors (Baillie Gifford, Wellington, Vanguard) materially increased stakes.

Shares of Axon Enterprise, Inc (NASDAQ:AXON - Get Free Report) hit a new 52-week low during trading on Tuesday . The company traded as low as $387.80 and last traded at $391.4010, with a volume of 159891 shares traded. The stock had previously closed at $413.07.

Analysts Set New Price Targets

AXON has been the subject of a number of research analyst reports. Weiss Ratings reiterated a "hold (c-)" rating on shares of Axon Enterprise in a report on Friday, March 27th. Citigroup reiterated a "buy" rating on shares of Axon Enterprise in a report on Wednesday, February 25th. Royal Bank Of Canada cut their price target on Axon Enterprise from $860.00 to $735.00 and set an "outperform" rating for the company in a report on Wednesday, February 25th. Craig Hallum restated a "buy" rating and set a $820.00 price objective on shares of Axon Enterprise in a report on Wednesday, February 25th. Finally, UBS Group dropped their price objective on shares of Axon Enterprise from $610.00 to $570.00 and set a "neutral" rating on the stock in a report on Wednesday, February 25th. Sixteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $762.93.

Axon Enterprise Stock Down 6.8%

The business's fifty day moving average price is $478.24 and its 200 day moving average price is $575.44. The company has a market capitalization of $30.96 billion, a P/E ratio of 253.44, a P/E/G ratio of 8.81 and a beta of 1.61. The company has a current ratio of 2.53, a quick ratio of 2.29 and a debt-to-equity ratio of 0.53.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, topping analysts' consensus estimates of $1.60 by $0.55. The company had revenue of $796.72 million during the quarter, compared to the consensus estimate of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The firm's revenue for the quarter was up 38.5% compared to the same quarter last year. During the same period last year, the firm earned $2.08 EPS. As a group, equities research analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Insider Activity at Axon Enterprise

In other news, CAO Jennifer H. Mak sold 1,500 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $573.45, for a total value of $860,175.00. Following the completion of the transaction, the chief accounting officer directly owned 12,240 shares of the company's stock, valued at approximately $7,019,028. This represents a 10.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $500.24, for a total value of $5,002,400.00. Following the completion of the transaction, the chief executive officer directly owned 3,090,997 shares of the company's stock, valued at approximately $1,546,240,339.28. The trade was a 0.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 23,855 shares of company stock worth $13,299,928 in the last ninety days. Company insiders own 4.40% of the company's stock.

Hedge Funds Weigh In On Axon Enterprise

Several institutional investors have recently added to or reduced their stakes in AXON. Baillie Gifford & Co. lifted its holdings in Axon Enterprise by 1,198.7% during the 4th quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company's stock valued at $932,869,000 after purchasing an additional 1,516,099 shares during the last quarter. Edgewood Management LLC bought a new position in Axon Enterprise during the 4th quarter valued at about $846,516,000. Wellington Management Group LLP lifted its holdings in Axon Enterprise by 326.9% during the 4th quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company's stock valued at $874,463,000 after purchasing an additional 1,179,038 shares during the last quarter. Norges Bank bought a new position in Axon Enterprise during the 4th quarter valued at about $515,764,000. Finally, Vanguard Group Inc. lifted its holdings in Axon Enterprise by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company's stock valued at $6,684,217,000 after purchasing an additional 376,904 shares during the last quarter. 79.08% of the stock is owned by institutional investors.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company's hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.